LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
LIXT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US5393191110 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 433 PLAZA REAL, 33432 BOCA RATON
- Website:
- https://lixte.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of oncology treatments. The company has pioneered the development of Protein Phosphatase 2A (PP2A) inhibitors as a new therapeutic approach. Its lead product candidate, LB-100, is a first-in-class molecule designed to enhance the efficacy of both chemotherapy and immunotherapy. By targeting the critical PP2A enzyme, LB-100 aims to overcome treatment resistance, increase the effectiveness of existing cancer therapies, and improve outcomes for a broad range of patients and cancer types.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all LIXTE BIOTECHNOLOGY HOLDINGS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for LIXTE BIOTECHNOLOGY HOLDINGS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for LIXTE BIOTECHNOLOGY HOLDINGS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
